BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 237-64. [DOI: 10.1007/164_2019_241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Benić MS, Nežić L, Vujić-Aleksić V, Mititelu-Tartau L. Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review. Front Pharmacol 2021;12:785790. [PMID: 35185538 DOI: 10.3389/fphar.2021.785790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ong ASK, Aw MM, Goh DL, Karthik SV. Cholestatic Jaundice in Sulphite Oxidase Deficiency - An Unusual Association. Indian J Pediatr 2021;88:64-6. [PMID: 32648099 DOI: 10.1007/s12098-020-03428-3] [Reference Citation Analysis]
3 Zou M, Wang A, Wei J, Cai H, Yu Z, Zhang L, Wang X. An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis. Int Immunopharmacol 2021;92:107328. [PMID: 33412394 DOI: 10.1016/j.intimp.2020.107328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Contreras-Omaña R, Velarde-Ruiz Velasco JA, Castro-Narro GE, Trujillo-Benavides O, Zamarripa-Dorsey F, Reyes-Dorantes AA, Muñoz-Espinosa L, Aiza-Haddad I, Castillo-Barradas M, Cerda-Reyes E, Cisneros-Garza LE, Flores-Calderón J, García-Jiménez ES, Higuera-de-la-Tijera MF, Lira-Pedrín MA, Marquez-Guillén E, Moctezuma-Velázquez C, Moreno-Alcántar R, Noyola-Cedillo SG, Pérez-Hernández JL, Ramos-Gómez MV, Remes-Troche JM, Rizo-Robles MT, Rodríguez-Hernández H. Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00130-4. [PMID: 34866042 DOI: 10.1016/j.rgmxen.2021.04.003] [Reference Citation Analysis]
5 Win A, Delgado A, Jadeja RN, Martin PM, Bartoli M, Thounaojam MC. Pharmacological and Metabolic Significance of Bile Acids in Retinal Diseases. Biomolecules 2021;11:292. [PMID: 33669313 DOI: 10.3390/biom11020292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cao Y, Huang Z, You S, Guo W, Zhang F, Liu B, Lv X, Lin Z, Liu P. The Protective Effects of Ganoderic Acids from Ganoderma lucidum Fruiting Body on Alcoholic Liver Injury and Intestinal Microflora Disturbance in Mice with Excessive Alcohol Intake. Foods 2022;11:949. [DOI: 10.3390/foods11070949] [Reference Citation Analysis]
7 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
8 Zan B, Liu X, Zhao Y, Shi R, Sun X, Wang T, Li Y, Liu S, Yang L, Ma Y. A validated surrogate analyte UPLC-MS/MS assay for quantitation of TUDCA, TCDCA, UDCA and CDCA in rat plasma: Application in a pharmacokinetic study of cultured bear bile powder. Biomed Chromatogr 2020;34:e4835. [PMID: 32198899 DOI: 10.1002/bmc.4835] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ibrahim SH, Kamath BM, Loomes KM, Karpen SJ. Cholestatic liver diseases of genetic etiology: Advances and controversies. Hepatology 2022;75:1627-46. [PMID: 35229330 DOI: 10.1002/hep.32437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Zhang XH, Li JY, Gao JS. Significance of expression of lncRNA-ATB in serum of patients with cholestatic liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(21): 1320-1325 [DOI: 10.11569/wcjd.v27.i21.1320] [Reference Citation Analysis]
11 Feng L, Zhang W, Shen Q, Miao C, Chen L, Li Y, Gu X, Fan M, Ma Y, Wang H, Liu X, Zhang X. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J Cachexia Sarcopenia Muscle 2021. [PMID: 34585527 DOI: 10.1002/jcsm.12798] [Reference Citation Analysis]
12 Lajczak-McGinley NK, Porru E, Fallon CM, Smyth J, Curley C, McCarron PA, Tambuwala MM, Roda A, Keely SJ. The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis. Physiol Rep 2020;8:e14456. [PMID: 32562381 DOI: 10.14814/phy2.14456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
13 Thounaojam MC, Jadeja RN, Rajpurohit S, Gutsaeva DR, Stansfield BK, Martin PM, Bartoli M. Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. J Clin Med 2020;9:E1921. [PMID: 32575487 DOI: 10.3390/jcm9061921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Huang R, Huang Y, Zeng G, Li M, Jin Y. Ursodeoxycholic acid inhibits intimal hyperplasia, vascular smooth muscle cell excessive proliferation, migration via blocking miR-21/PTEN/AKT/mTOR signaling pathway. Cell Cycle 2020;19:918-32. [PMID: 32202193 DOI: 10.1080/15384101.2020.1732514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Fiorucci S, Distrutti E. The Pharmacology of Bile Acids and Their Receptors. Handb Exp Pharmacol. 2019;256:3-18. [PMID: 31201555 DOI: 10.1007/164_2019_238] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
16 Łukawska A, Mulak A. Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection. Polish Journal of Microbiology 2022;0. [DOI: 10.33073/pjm-2022-007] [Reference Citation Analysis]
17 Khalaf K, Tornese P, Cocco A, Albanese A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener 2022;11:33. [PMID: 35659112 DOI: 10.1186/s40035-022-00307-z] [Reference Citation Analysis]
18 Fiorucci S, Distrutti E. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 265-82. [DOI: 10.1007/164_2019_226] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
19 Liu SY, Chang LW, Wang J, Xie M, Chen LL, Liu W. Ursodeoxycholic acid prevention on cholestasis associated with total parenteral nutrition in preterm infants: a randomized trial. World J Pediatr 2022. [PMID: 34988851 DOI: 10.1007/s12519-021-00487-0] [Reference Citation Analysis]
20 Bassendine MF, Taylor-Robinson SD, Fertleman M, Khan M, Neely D. Is Alzheimer's Disease a Liver Disease of the Brain? J Alzheimers Dis 2020;75:1-14. [PMID: 32250293 DOI: 10.3233/JAD-190848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
21 He L, Guo C, Peng C, Li Y. Advances of natural activators for Nrf2 signaling pathway on cholestatic liver injury protection: a review. Eur J Pharmacol 2021;910:174447. [PMID: 34461126 DOI: 10.1016/j.ejphar.2021.174447] [Reference Citation Analysis]
22 Shi K, Wen J, Zeng J, Guo Y, Hu J, Li C, Zhao Y, Ma X. Preclinical evidence of Yinchenhao decoction on cholestasis: A systematic review and meta-analysis of animal studies. Phytother Res 2021;35:138-54. [PMID: 32975338 DOI: 10.1002/ptr.6806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]